Log in Free sign up

Opiant Pharmaceuticals (OPNT) News and press releases

News

From Benzinga Pro

110 Biggest Movers From Friday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 154.9% to close at $0.51. ShiftPixy reported board approval special dividend to shareholders in form of common shares of Industrial Human Capital.

Stocks That Hit 52-Week Lows On Friday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Friday, 153 companies set new 52-week lows.

OPNT: Positive Results for Pharmacodynamic Trial of OPNT003…

By David Bautz, PhD NASDAQ:OPNT READ THE FULL OPNT RESEARCH REPORT

99 Biggest Movers From Yesterday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Armstrong Flooring, Inc. (NYSE: AFI) shares jumped 237% to settle at $0.49 on Wednesday after a 13D filing showed Esopus Creek Advisors LLC disclosed a 5.1% active stake in the company.

12 Health Care Stocks Moving In Wednesday's Intraday Session

Intraday Update, Markets, Movers

Opiant Pharmaceuticals Q1 EPS $(2.43) Down From $(0.66) YoY, Sales $4.47M Miss $5.90M Estimate

Opiant Pharmaceuticals (NASDAQ:OPNT) reported quarterly losses of $(2.43) per share. This is a 268.18 percent decrease over losses of $(0.66) per share from the same period last year. The company reported quarterly

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves

Biotech, Earnings, M&A, News, Penny Stocks, Guidance, Health Care, Financing, Offerings, Small Cap, FDA, Management, Movers, Trading Ideas, General

Here's a roundup of top developments in the biotech space over the last 24 hours:

Earnings Scheduled For May 10, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.

A Preview Of Opiant Pharmaceuticals's Earnings

Opiant Pharmaceuticals (NASDAQ:OPNT) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Opiant Pharmaceuticals will report an earnings per share (EPS) of $-0.91.

70 Biggest Movers From Friday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers GTY Technology Holdings Inc. (NASDAQ: GTYH) shares climbed 115.2% to close at $6.09 as the company agreed to be acquired by GI Partners.

12 Health Care Stocks Moving In Friday's Intraday Session

Intraday Update, Markets, Movers

48 Stocks Moving In Friday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Belite Bio Inc. ADR (NASDAQ: BLTE) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS.

Opiant Pharmaceuticals Says To 'Disregard' Prior News Of $225M Licensing Agreement; Says Intial Release 'Contains Incorrect Information

News, Contracts, FDA

We are advised by Opiant Pharmaceuticals that journalists and other readers should disregard the news release, Opiant Pharmaceuticals and Hikma announce exclusive $225 million commercialisation and license agreement for

Opiant Pharmaceuticals And Hikma Earlier Announced Exclusive $225M Commercialization And License Agreement For OPNT003, Nasal Nalmefene, In Europe And UK

News, Contracts, FDA

https://www.yahoo.com/now/opiant-pharmaceuticals-hikma-announce-exclusive-131500021.html

The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates

Biotech, Earnings, Large Cap, News, Penny Stocks, Guidance, Health Care, Contracts, Small Cap, FDA, Movers, Trading Ideas, General

Here's a roundup of top developments in the biotech space over the last 24 hours:

Why Opiant Pharmaceuticals Shares Are Soaring Today

Biotech, News, Health Care, Movers, Trading Ideas, General

President Biden To Outline Strategy To Tackle Drug Addiction, Overdose: Reuters

Biotech, Government, News, Health Care, Legal, General

OPNT: Data from OPNT003 Pharmacodynamic Trial in 2Q22…

By David Bautz, PhD NASDAQ:OPNT READ THE FULL OPNT RESEARCH REPORT

Looking Into Opiant Pharmaceuticals's Return On Capital Employed

According to Benzinga Pro, during Q4, Opiant Pharmaceuticals (NASDAQ:OPNT) earned $752.33 thousand, a 77.98% increase from the preceding quarter. Opiant Pharmaceuticals's sales decreased to $13.80 million, a 15.54% change since Q3.

Opiant Pharmaceuticals: Q4 Earnings Insights

Opiant Pharmaceuticals (NASDAQ:OPNT) reported its Q4 earnings results on Tuesday, March 15, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Press releases

From Benzinga Pro

Opiant Pharmaceuticals to Hold Virtual 2022 Annual Shareholder Meeting on Tuesday, June 14, 2022 at 9:00am PDT

News, Press Releases

SANTA MONICA, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), announced today that to protect the health and safety of its shareholders, employees, and communities amidst

Opiant Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update

Earnings, News, Press Releases

SANTA MONICA, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today

Opiant Pharmaceuticals Issues Statement in Response to Fake Press Release

SANTA MONICA, Calif., April 29, 2022 /PRNewswire/ -- Opiant Pharmaceuticals (NASDAQ:OPNT) was the subject of a fake news release issued on Friday, April 29, 2022, that falsely stated Opiant announced a partnership with

Opiant Pharmaceuticals Announces Positive Topline Results from Head-to-Head Pharmacodynamic Study Comparing OPNT003, Nasal Nalmefene, to Nasal Naloxone

Health Care, Press Releases

Study compared OPNT003, nasal nalmefene, with 4 mg nasal naloxone hydrochloride in reversing the respiratory depression produced by remifentanil, a synthetic opioidOPNT003 met the primary endpoint of non-inferiority,

Opiant Pharmaceuticals Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

Earnings, Press Releases

SANTA MONICA, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today

Opiant Pharmaceuticals to Participate in 32nd Oppenheimer Healthcare Conference

News, Health Care, Press Releases

SANTA MONICA, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced

Opiant Pharmaceuticals to Report Fourth Quarter 2021 Financial Results and Host Conference Call and Webcast on March 15, 2022

News, Press Releases

SANTA MONICA, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced